Compare IIIV & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIV | PALI |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.2M | 359.7M |
| IPO Year | 2018 | 2019 |
| Metric | IIIV | PALI |
|---|---|---|
| Price | $20.04 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $33.20 | $11.29 |
| AVG Volume (30 Days) | 409.0K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | $247.56 | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $18.47 | $0.55 |
| 52 Week High | $33.97 | $2.86 |
| Indicator | IIIV | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 50.65 |
| Support Level | $18.82 | $1.57 |
| Resistance Level | $23.62 | $2.12 |
| Average True Range (ATR) | 0.93 | 0.14 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 30.73 | 46.00 |
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.